Alexandra Kolenová1, Dušan Rada1, Zuzana Šubová1, Lucia Copáková2, Daniela Sejnová1, Emília Kaiserová1
Roughly every third child with AML carries one of the three most commonly occuring balanced translocations t(15;17), t(8;21) and t(16;16) that bear the most favourable prognosis. Survival rates grow continuously due to improvements in risk adapted intensive chemotherapy and optimised supportive care. The results of the recent clinical study AML-BFM 2004 report the overall survival of children up to ~70 %; while in case of favourable cytogenetics even up to 90 %. The goal of this paper is to use the example of three case histories of AML with favourable cytogenetic markers to illustrate the current management of pediatric patients treated in the Department of Pediatric Hematology and Oncology LF UK and DFNsP in Bratislava and to analyse the achieved results.